Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,519.12
(
0.61%
)
US TECH 100
29,229.20
(
1.84%
)
Dow Jones
50,461.68
(
-0.23%
)
Brent Oil
95.27
(
-1.77%
)
Bitcoin
75,535.35
(
-0.41%
)
News Focus
News Focus
Post# of 257644
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123024
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 151412

Tuesday, 10/30/2012 6:59:23 PM

Tuesday, October 30, 2012 6:59:23 PM

Post# of 257644
Among neurotoxins, Botox had a 95% (!) US market share in therapeutic indications and an 82% US market share in cosmetic indications during 2Q12, the most recent quarter for which market-share data are available. (Source: AGN 3Q12 CC.) Dysport, Xeomin, and Myobloc make up the rest of the US market.

Xeomin’s US market share has been artificially low due to the court injunction that runs until 11/1/12 for therapeutic indications and 1/9/13 for cosmetic indications (#msg-80110811).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today